- Home
- SNPX vs INM Comparison
SNPX vs INM Comparison
Compare SNPX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNPX
- INM
- Stock Information
- Founded
- SNPX 2012
- INM 1981
- Country
- SNPX United States
- INM Canada
- Employees
- SNPX N/A
- INM N/A
- Industry
- SNPX Medicinal Chemicals and Botanical Products
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SNPX Health Care
- INM Health Care
- Exchange
- SNPX Nasdaq
- INM Nasdaq
- Market Cap
- SNPX 3.7M
- INM 3.4M
- IPO Year
- SNPX N/A
- INM N/A
- Fundamental
- Price
- SNPX $3.30
- INM $4.95
- Analyst Decision
- SNPX Strong Buy
- INM
- Analyst Count
- SNPX 1
- INM 0
- Target Price
- SNPX $14.00
- INM N/A
- AVG Volume (30 Days)
- SNPX 33.7K
- INM 26.6K
- Earning Date
- SNPX 11-12-2024
- INM 02-11-2025
- Dividend Yield
- SNPX N/A
- INM N/A
- EPS Growth
- SNPX N/A
- INM N/A
- EPS
- SNPX N/A
- INM N/A
- Revenue
- SNPX N/A
- INM $4,960,506.00
- Revenue This Year
- SNPX N/A
- INM N/A
- Revenue Next Year
- SNPX N/A
- INM N/A
- P/E Ratio
- SNPX N/A
- INM N/A
- Revenue Growth
- SNPX N/A
- INM 5.17
- 52 Week Low
- SNPX $2.32
- INM $2.42
- 52 Week High
- SNPX $7.23
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SNPX 51.02
- INM 55.90
- Support Level
- SNPX $3.10
- INM $4.07
- Resistance Level
- SNPX $3.58
- INM $5.41
- Average True Range (ATR)
- SNPX 0.33
- INM 0.39
- MACD
- SNPX -0.03
- INM 0.01
- Stochastic Oscillator
- SNPX 32.04
- INM 67.83
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.